dsip mastery course
Unit 10 of 11

regulatory outlook

why development stalled, what analogs exist, and where the field stands

the lessons of a promising compound that never became a medicine

DSIP has no FDA approval, no active ClinicalTrials.gov registration as of 2026, and no clear development pathway. The reasons are instructive: no confirmed receptor makes regulatory target validation impossible, PK instability creates CMC challenges, and historical positive studies cannot overcome the requirement for modern confirmatory trials. Understanding why promising peptides fail to become medicines is one of the most useful lessons DSIP teaches about the drug-development process.

0 FDA approvals
any indication
0 ClinicalTrials entries
as of 2026
gray market
US regulatory status
analogs attempted
none advanced to clinical
no IND filed
investigational new drug path
47+ years
since discovery, still unregulated

regulatory timeline

Trace the history of DSIP's regulatory non-development from 1977 to the present.

barriers to development

  • no receptor: target validation required for IND filing
  • PK instability: rapid proteolysis -- CMC challenge
  • historical data: pre-GCP trials unacceptable as evidence

what would change the picture

  • receptor identification: opens IND pathway
  • stable analog: solves CMC + improves bioavailability
  • modern RCT: Phase 2 confirmatory trial needed
regulatory timeline